Review ArticleReview

Key questions about the checkpoint blockade-are microRNAs an answer?

Mihnea Dragomir, Baoqing Chen, Xiao Fu and George A. Calin
Cancer Biology & Medicine May 2018, 15 (2) 103-115; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0006

References

  1. 1.↵
    2. Hodi FS,
    3. O’Day SJ,
    4. McDermott DF,
    5. Weber RW,
    6. Sosman JA,
    7. Haanen JB, et al.
    Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711–23.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Robert C,
    3. Thomas L,
    4. Bondarenko I,
    5. O’Day S,
    6. Weber J,
    7. Garbe C, et al.
    Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517–26.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    2. Robert C,
    3. Schachter J,
    4. Long GV,
    5. Arance A,
    6. Grob JJ,
    7. Mortier L, et al.
    Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372: 2521–32.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Robert C,
    3. Long GV,
    4. Brady B,
    5. Dutriaux C,
    6. Maio M,
    7. Mortier L, et al.
    Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372: 320–30.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    2. Garon EB,
    3. Rizvi NA,
    4. Hui R,
    5. Leighl N,
    6. Balmanoukian AS,
    7. Eder JP, et al.
    Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372: 2018–28.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Brahmer J,
    3. Reckamp KL,
    4. Baas P,
    5. Crino L,
    6. Eberhardt WEE,
    7. Poddubskaya E, et al.
    Nivolumab versus docetaxel in advanced Squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373: 123–35.
    OpenUrlCrossRefPubMed
  7. 7.↵
    U.S. Food and Drug Administration. FDA approves new, targeted treatment for bladder cancer. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm.
  8. 8.↵
    U.S. Food and Drug Administration. Atezolizumab (TECENTRIQ). https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm.
  9. 9.↵
    U.S. Food and Drug Administration. FDA approves first treatment for rare form of skin cancer. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm548278.htm.
  10. 10.↵
    U.S. Food and Drug Administration. Durvalumab (Imfinzi). https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555930.htm.
  11. 11.↵
    U.S. Food and Drug Administration. FDA approves first cancer treatment for any solid tumor with a specific genetic feature. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm560167.htm.
  12. 12.↵
    Bristol-Myers-Squibb. Bristol-myers squibb receives FDA approval for opdivo (nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer. https://news.bms.com/press-release/bladdercancer/bristol-myerssquibb-receives-fda-approval-opdivo-nivolumab-previously-t.
  13. 13.↵
    2. Bullrich F,
    3. Fujii H,
    4. Calin G,
    5. Mabuchi H,
    6. Negrini M,
    7. Pekarsky Y, et al
    . Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001; 61: 6640–8.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    2. Baek D,
    3. Villén J,
    4. Shin C,
    5. Camargo FD,
    6. Gygi SP,
    7. Bartel DP
    . The impact of microRNAs on protein output. Nature. 2008; 455: 64–71.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    2. Bartel DP
    . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215–33.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    2. Calin GA,
    3. Dumitru CD,
    4. Shimizu M,
    5. Bichi R,
    6. Zupo S,
    7. Noch E, et al.
    Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002; 99: 15524–9.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    2. Munker R,
    3. Calin GA
    . MicroRNA profiling in cancer. Clin Sci. 2011; 121: 141–58.
    OpenUrl
  18. 18.↵
    2. Arenz C
    2. Hesse M,
    3. Arenz C
    . MicroRNA maturation and human disease. In: Arenz C miRNA Maturation: Methods and Protocols. Totowa, NJ: Humana Press. 2014; 1095: 11–25.
    OpenUrl
  19. 19.↵
    2. Friedman RC,
    3. Farh KKH,
    4. Burge CB,
    5. Bartel DP
    . Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009; 19: 92–105.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Vasilescu C,
    3. Dragomir M,
    4. Tanase M,
    5. Giza D,
    6. Purnichescu-Purtan R,
    7. Chen M, et al.
    Circulating miRNAs in sepsis-A network under attack: An in-silico prediction of the potential existence of miRNA sponges in sepsis. PLoS One. 2017; 12: e0183334.
  21. 21.↵
    2. Volinia S,
    3. Galasso M,
    4. Costinean S,
    5. Tagliavini L,
    6. Gamberoni G,
    7. Drusco A, et al.
    Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010; 20: 589–99.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    2. Smolle MA,
    3. Calin HN,
    4. Pichler M,
    5. Calin GA
    . Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. FEBS J. 2017; 284: 1952–66.
    OpenUrl
  23. 23.↵
    2. Grenda A,
    3. Krawczyk P
    . New dancing couple: PD-L1 and MicroRNA. Scand J Immunol. 2017; 86: 130–4.
    OpenUrl
  24. 24.↵
    2. Giza DE,
    3. Vasilescu C,
    4. Calin GA
    . MicroRNAs and ceRNAs: therapeutic implications of RNA networks. Expert Opin Biol Ther. 2014; 14: 1285–93.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Pardoll DM
    . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252–64.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    2. Xu SH,
    3. Tao Z,
    4. Hai B,
    5. Liang HG,
    6. Shi Y,
    7. Wang T, et al.
    miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 2016; 7: 11406.
    OpenUrl
  27. 27.↵
    2. Huang YH,
    3. Zhu C,
    4. Kondo Y,
    5. Anderson AC,
    6. Gandhi A,
    7. Russell A, et al.
    CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015; 517: 386–90.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Goncalves Silva I,
    3. Yasinska IM,
    4. Sakhnevych SS,
    5. Fiedler W,
    6. Wellbrock J,
    7. Bardelli M, et al.
    The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells. EBioMedicine. 2017; 22: 44–57.
    OpenUrl
  29. 29.↵
    2. Jiang XW,
    3. Zhou TT,
    4. Xiao Y,
    5. Yu JH,
    6. Dou SJ,
    7. Chen GJ, et al.
    Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis. Oncoimmunology. 2016; 5: e1211219.
  30. 30.↵
    2. Weng CY,
    3. Nguyen T,
    4. Shively JE
    . miRNA-342 regulates CEACAM1-induced lumen formation in a three-dimensional model of mammary gland morphogenesis. J Biol Chem. 2016; 291: 16777–86.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    2. Tadokoro T,
    3. Fujihara S,
    4. Chiyo T,
    5. Oura K,
    6. Samukawa E,
    7. Yamana Y, et al.
    Induction of apoptosis by Galectin-9 in liver metastatic cancer cells: in vitro study. Int J Oncol. 2017; 51: 607–14.
    OpenUrl
  32. 32.↵
    2. Yang J,
    3. Liu RH,
    4. Deng YT,
    5. Qian JW,
    6. Lu Z,
    7. Wang YD, et al.
    MiR-15a/16 deficiency enhances anti-tumor immunity of glioma-infiltrating CD8+ T cells through targeting mTOR. Int J Cancer. 2017; 141: 2082–92.
    OpenUrlCrossRef
  33. 33.↵
    2. Wei J,
    3. Nduom EK,
    4. Kong LY,
    5. Hashimoto Y,
    6. Xu S,
    7. Gabrusiewicz K, et al.
    MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016; 18: 639–48.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. Zhao L,
    3. Yu HB,
    4. Yi SJ,
    5. Peng XW,
    6. Su P,
    7. Xiao ZM, et al.
    The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer. Oncotarget. 2016; 7: 45370–84.
    OpenUrl
  35. 35.↵
    2. Li Q,
    3. Johnston N,
    4. Zheng XF,
    5. Wang HM,
    6. Zhang XS,
    7. Gao D, et al.
    miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget. 2016; 7: 53735–50.
    OpenUrl
  36. 36.↵
    2. Torphy RJ,
    3. Schulick RD,
    4. Zhu YW
    . Newly emerging immune checkpoints: promises for future cancer therapy. Int J Mol Sci. 2017; 18: 2642.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Liu YA,
    3. Nie W,
    4. Jin Y,
    5. Zhuo AS,
    6. Zang YS,
    7. Xiu QY
    . B and T lymphocyte attenuator is a target of miR-155 during naive CD4+ T cell activation. Iran J Immunol. 2016; 13: 89–99.
    OpenUrl
  38. 38.↵
    2. Veenstra RG,
    3. Flynn R,
    4. Kreymborg K,
    5. McDonald-Hyman C,
    6. Saha A,
    7. Taylor PA, et al.
    B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015; 125: 3335–46.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    2. Nygren MK,
    3. Tekle C,
    4. Ingebrigtsen VA,
    5. Mäkelä R,
    6. Krohn M,
    7. Aure MR, et al.
    Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer. 2014; 110: 2072–80.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Sharpe AH,
    3. Wherry EJ,
    4. Ahmed R,
    5. Freeman GJ
    . The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007; 8: 239–45.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    2. Herbst RS,
    3. Soria JC,
    4. Kowanetz M,
    5. Fine GD,
    6. Hamid O,
    7. Gordon MS, et al.
    Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563–7.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    2. Wang WP,
    3. Sun J,
    4. Li F,
    5. Li R,
    6. Gu YP,
    7. Liu CP, et al.
    A frequent somatic mutation in CD274 3'-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat. 2012; 33: 480–4.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. Cortez MA,
    3. Ivan C,
    4. Valdecanas D,
    5. Wang XH,
    6. Peltier HJ,
    7. Ye YP, et al.
    PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016; 108: djv303.
    OpenUrlCrossRefPubMed
  44. 44.↵
    2. Wang X,
    3. Li JG,
    4. Dong K,
    5. Lin F,
    6. Long M,
    7. Ouyang YR, et al.
    Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015; 27: 443–52.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Pyzer AR,
    3. Stroopinsky D,
    4. Rosenblatt J,
    5. Anastasiadou E,
    6. Rajabi H,
    7. Washington A, et al.
    MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. 2017; 31: 2780–90.
    OpenUrlCrossRef
  46. 46.↵
    2. Fujita Y,
    3. Yagishita S,
    4. Hagiwara K,
    5. Yoshioka Y,
    6. Kosaka N,
    7. Takeshita F, et al.
    The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer. Mol Ther. 2015; 23: 717–27.
    OpenUrlCrossRefPubMed
  47. 47.↵
    2. Niu GL,
    3. Wright KL,
    4. Ma YH,
    5. Wright GM,
    6. Huang M,
    7. Irby R, et al.
    Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005; 25: 7432–40.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    2. Kao SC,
    3. Cheng YY,
    4. Williams M,
    5. Kirschner MB,
    6. Madore J,
    7. Lum T, et al.
    Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma. J Thorac Oncol. 2017; 12: 1421–33.
    OpenUrlPubMed
  49. 49.↵
    2. Chen LM,
    3. Gibbons DL,
    4. Goswami S,
    5. Cortez MA,
    6. Ahn YH,
    7. Byers LA, et al.
    Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014; 5: 5241.
    OpenUrlCrossRefPubMed
  50. 50.↵
    2. Zhu JJ,
    3. Chen LX,
    4. Zou LT,
    5. Yang PP,
    6. Wu RR,
    7. Mao Y, et al.
    MiR-20b, -21, and-130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol. 2014; 75: 348–53.
    OpenUrlCrossRefPubMed
  51. 51.↵
    2. Zou MX,
    3. Guo KM,
    4. Lv GH,
    5. Huang W,
    6. Li J,
    7. Wang XB, et al.
    Clinicopathologic implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients. Cancer Immunol Immunother. 2018; 67: 209–24.
    OpenUrl
  52. 52.↵
    2. Ahn H,
    3. Yang JM,
    4. Kim H,
    5. Chung JH,
    6. Ahn SH,
    7. Jeong WJ, et al.
    Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget. 2017; 8: 66178–94.
    OpenUrl
  53. 53.↵
    2. Cioffi M,
    3. Trabulo SM,
    4. Vallespinos M,
    5. Raj D,
    6. Kheir TB,
    7. Lin ML, et al.
    The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget. 2017; 8: 21609–25.
    OpenUrl
  54. 54.↵
    2. Pandya D,
    3. Mariani M,
    4. He SQ,
    5. Andreoli M,
    6. Spennato M,
    7. Dowell-Martino C, et al.
    Epstein-barr virus MicroRNA expression increases aggressiveness of solid malignancies. PLoS One. 2015; 10: e0136058.
  55. 55.↵
    2. Baer C,
    3. Squadrito ML,
    4. Laoui D,
    5. Thompson D,
    6. Hansen SK,
    7. Kiialainen A, et al.
    Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity. Nat Cell Biol. 2016; 18: 790–802.
    OpenUrlCrossRefPubMed
  56. 56.↵
    2. Huffaker TB,
    3. Lee SH,
    4. Tang WW,
    5. Wallace JA,
    6. Alexander M,
    7. Runtsch MC, et al.
    Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem. 2017; 292: 18530–41.
    OpenUrlAbstract/FREE Full Text
  57. 57.↵
    2. Yee D,
    3. Shah KM,
    4. Coles MC,
    5. Sharp TV,
    6. Lagos D
    . MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem. 2017; 292: 20683–93.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    2. Gong AY,
    3. Zhou R,
    4. Hu GK,
    5. Li XQ,
    6. Splinter PL,
    7. O'Hara SP, et al.
    MicroRNA-513 regulates B7-H1 translation and is involved in IFN-γ-induced B7-H1 expression in cholangiocytes. J Immunol. 2009; 182: 1325–33.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    2. Wu L,
    3. Chen Z,
    4. Zhang J,
    5. Xing YQ
    . Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells. J Huazhong Univ Sci Technol. 2012; 32: 601–6.
    OpenUrl
  60. 60.↵
    2. Sharma P,
    3. Allison JP
    . The future of immune checkpoint therapy. Science. 2015; 348: 56–61.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    2. Hopkins AM,
    3. Rowland A,
    4. Kichenadasse G,
    5. Wiese MD,
    6. Gurney H,
    7. McKinnon RA, et al.
    Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer. 2017; 117: 913–20.
    OpenUrlCrossRefPubMed
  62. 62.↵
    2. Nishino M,
    3. Ramaiya NH,
    4. Hatabu H,
    5. Hodi FS
    . Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017; 14: 655–68.
    OpenUrlCrossRefPubMed
  63. 63.↵
    2. Wolchok JD,
    3. Hoos A,
    4. O'Day S,
    5. Weber JS,
    6. Hamid O,
    7. Lebbé C, et al.
    Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412–20.
    OpenUrlAbstract/FREE Full Text
  64. 64.
    2. Nishino M,
    3. Jagannathan JP,
    4. Krajewski KM,
    5. O'Regan K,
    6. Hatabu H,
    7. Shapiro G, et al.
    Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol. 2012; 198: 737–45.
    OpenUrlCrossRefPubMed
  65. 65.↵
    2. Nishino M,
    3. Tirumani SH,
    4. Ramaiya NH,
    5. Hodi FS
    . Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015; 84: 1259–68.
    OpenUrlCrossRefPubMed
  66. 66.↵
    U.S. Food and Drug Administration. Pembrolizumab (KEYTRUDA) checkpoint inhibitor. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm526430.htm.
  67. 67.↵
    2. Audrito V,
    3. Serra S,
    4. Stingi A,
    5. Orso F,
    6. Gaudino F,
    7. Bologna C, et al.
    PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget. 2017; 8: 15894–911.
    OpenUrl
  68. 68.↵
    2. Friedman CF,
    3. Proverbs-Singh TA,
    4. Postow MA
    . Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016; 2: 1346–53.
    OpenUrlPubMed
  69. 69.↵
    2. Weber JS,
    3. Kähler KC,
    4. Hauschild A
    . Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30: 2691–7.
    OpenUrlAbstract/FREE Full Text
  70. 70.
    2. Larkin J,
    3. Chiarion-Sileni V,
    4. Gonzalez R,
    5. Grob JJ,
    6. Cowey CL,
    7. Lao CD, et al.
    Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23–34.
    OpenUrlCrossRefPubMed
  71. 71.↵
    2. Hodi FS,
    3. Postow MA,
    4. Chesney JA,
    5. Pavlick AC,
    6. Robert C,
    7. Grossmann KF, et al.
    Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. J Clin Oncol. 2015; 33: 9004.
    OpenUrl
  72. 72.↵
    2. Corsello SM,
    3. Barnabei A,
    4. Marchetti P,
    5. De Vecchis L,
    6. Salvatori R,
    7. Torino F
    . Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013; 98: 1361–75.
    OpenUrlCrossRefPubMedWeb of Science
  73. 73.↵
    2. Sarnaik AA,
    3. Yu B,
    4. Yu DH,
    5. Morelli D,
    6. Hall M,
    7. Bogle D, et al.
    Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res. 2011; 17: 896–906.
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    2. Zhang JY,
    3. Braun MY
    . PD-1 deletion restores susceptibility to experimental autoimmune encephalomyelitis in miR-155-deficient mice. Int Immunol. 2014; 26: 407–15.
    OpenUrlCrossRefPubMed
  75. 75.↵
    2. Sonkoly E,
    3. Janson P,
    4. Majuri ML,
    5. Savinko T,
    6. Fyhrquist N,
    7. Eidsmo L, et al.
    MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol. 2010; 126: 581–9.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    2. Zhang YY,
    3. Sun ET,
    4. Li XQ,
    5. Zhang M,Y Tang ZS,
    6. He L, et al.
    miR-155 contributes to Df1-induced asthma by increasing the proliferative response of Th cells via CTLA-4 downregulation. Cell Immunol. 2017; 314: 1–9.
    OpenUrl
  77. 77.↵
    2. Maio M,
    3. Grob JJ,
    4. Aamdal S,
    5. Bondarenko I,
    6. Robert C,
    7. Thomas L, et al.
    Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015; 33: 1191–6.
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    2. Ling H,
    3. Fabbri M,
    4. Calin GA
    . MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013; 12: 847–65.
    OpenUrlCrossRefPubMed
  79. 79.↵
    2. Tang YY,
    3. He Y,
    4. Shi L,
    5. Yang LT,
    6. Wang JP,
    7. Lian Y, et al.
    Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma. Oncotarget. 2017; 8: 39001–11.
    OpenUrlCrossRef
  80. 80.↵
    2. Dragomir M,
    3. Chen BQ,
    4. Calin GA
    . Exosomal lncRNAs as new players in cell-to-cell communication. Transl Cancer Res. 2017; 7: S243–52.
    OpenUrl
  81. 81.↵
    2. Braicu C,
    3. Tomuleasa C,
    4. Monroig P,
    5. Cucuianu A,
    6. Berindan-Neagoe I,
    7. Calin GA
    . Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 2015; 22: 34–45.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords